+19.0%
MARA vs MRNA
+34.8%
-15.8%
-78.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.8% | +5.4% | -0.6% | +4.2% |
| 7D | +5.9% | -1.1% | +7.0% | +6.0% |
| 30D | +24.3% | +126.1% | -101.8% | +2.4% |
| 3M | -12.0% | +190.0% | -202.0% | -33.7% |
| 6M | +40.1% | +157.2% | -117.1% | +8.8% |
| YTD | +33.4% | +388.2% | -354.8% | -14.1% |
| 1Y | -23.7% | +467.0% | -490.8% | -53.4% |
| 3Y | +19.0% | +36.1% | -17.1% | -4.8% |
| All | +19.0% | +34.8% | -15.8% | -4.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling